Nephros (NasdaqCM:NEPH) - Share price, News & Analysis

NEPH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

NEPH Stock Overview

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States.

Rewards

Revenue is forecast to grow 25% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($18M)

Nephros Competitors

NYSE:MMM

US$81.8b

Baxter International

NYSE:BAX

US$36.9b

Fresenius Medical Care KGaA

XTRA:FME

€16.5b

Pentair

NYSE:PNR

US$8.1b

Price History & Performance

Summary of all time highs, changes and price drops for Nephros
Historical stock prices
Current Share Price	US$1.79
52 Week High	US$11.67
52 Week Low	US$1.74
Beta	1.23
1 Month Change	-60.31%
3 Month Change	-60.40%
1 Year Change	-77.90%
3 Year Change	-66.00%
5 Year Change	-33.70%
Change since IPO	-99.83%

Shareholder Returns

	NEPH	US Consumer Durables	US Market
7D	-12.7%	-2.8%	-2.7%
1Y	-77.9%	-27.5%	-12.9%

Return vs Industry: NEPH underperformed the US Consumer Durables industry which returned -28.5% over the past year.

Return vs Market: NEPH underperformed the US Market which returned -12.7% over the past year.

Price Volatility

Is NEPH's price volatile compared to industry and market?
NEPH volatility
NEPH Average Weekly Movement	15.1%
Consumer Durables Industry Average Movement	7.8%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.0%

Stable Share Price: NEPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: NEPH's weekly volatility has increased from 10% to 15% over the past year.

About the Company

Founded	Employees	CEO	Website
1997	34	Andy Astor	https://www.nephros.com

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Nephros Fundamentals Summary

How do Nephros's earnings and revenue compare to its market cap?
NEPH fundamental statistics
Market Cap	US$18.47m
Earnings (TTM)	-US$5.54m
Revenue (TTM)	US$9.86m

1.9x

P/S Ratio

-3.3x

P/E Ratio

Is NEPH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
NEPH income statement (TTM)
Revenue	US$9.86m
Cost of Revenue	US$4.67m
Gross Profit	US$5.18m
Other Expenses	US$10.72m
Earnings	-US$5.54m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.54
Gross Margin	52.57%
Net Profit Margin	-56.23%
Debt/Equity Ratio	2.1%

How did NEPH perform over the long term?

See historical performance and comparison

Valuation

Is Nephros undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

1.82x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NEPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NEPH's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: NEPH is unprofitable, so we can't compare its PE Ratio to the US Consumer Durables industry average.

PE vs Market: NEPH is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NEPH's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: NEPH is overvalued based on its PB Ratio (1.8x) compared to the US Consumer Durables industry average (1.3x).

Future Growth

How is Nephros forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

11.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NEPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NEPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NEPH's revenue (25% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: NEPH's revenue (25% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NEPH's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Nephros performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-17.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NEPH is currently unprofitable.

Growing Profit Margin: NEPH is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: NEPH is unprofitable, and losses have increased over the past 5 years at a rate of 17.6% per year.

Accelerating Growth: Unable to compare NEPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEPH is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Durables industry (45.1%).

Return on Equity

High ROE: NEPH has a negative Return on Equity (-39.52%), as it is currently unprofitable.

Financial Health

How is Nephros's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NEPH's short term assets ($11.7M) exceed its short term liabilities ($1.7M).

Long Term Liabilities: NEPH's short term assets ($11.7M) exceed its long term liabilities ($378.0K).

Debt to Equity History and Analysis

Debt Level: NEPH has more cash than its total debt.

Reducing Debt: NEPH's debt to equity ratio has reduced from 63.2% to 2.1% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NEPH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NEPH has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 10.9% each year.

Dividend

What is Nephros's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NEPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NEPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NEPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NEPH's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NEPH has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure

CEO

Andy Astor (64 yo)

1.75yrs

Tenure

US$545,724

Compensation

Mr. Andrew Astor, also known as Andy, serves as Chief Financial Officer at Nephros, Inc. since January 28, 2021. He has been Chief Executive Officer, President and Director of Nephros, Inc. since August 24...

CEO Compensation Analysis

Compensation vs Market: Andy's total compensation ($USD545.72K) is about average for companies of similar size in the US market ($USD771.97K).

Compensation vs Earnings: Andy's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: NEPH's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Experienced Board: NEPH's board of directors are considered experienced (3.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/21 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31